SCHEMBL8482325

SCHEMBL8482325

CCCCc1c2c(c(C(=O)OC(C)(C)C)c(F)c1N1CCCCC1N)-c1cc(F)ccc1C2C(=O)NCC(F)(F)F

nearest known ligand 0.32

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ NR3C2 P08235 2/20 0.32
▸ KCNA3 P22001 1/20 0.31
▸ KCNA5 P22460 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8484144 0.89 KCNA3 (0.32) NR3C2KCNA3KCNA5
SCHEMBL8669577 0.86 NR3C2 (0.31) NR3C2KCNA3KCNA5
SCHEMBL8504391 0.83 NR3C2 (0.30) NR3C2
SCHEMBL8479120 0.80 POLB (0.34) —
SCHEMBL8663542 0.78 POLB (0.34) —
SCHEMBL8486153 0.77 — —
SCHEMBL8665948 0.75 PGR (0.31) —
SCHEMBL8655292 0.74 POLB (0.32) —
SCHEMBL8479793 0.74 POLB (0.33) —
SCHEMBL8343961 0.72 HCRTR2 (0.34) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5883099-A TREATMENT OF ATHERSCLEROSIS, PANCREATITIS OBESITY OR HYPERGLYCEMIA BRISTOL-MYERS SQUIBB COMPANY (US) 1999-03-16 — — US disclosed
US-5739135-A PREVENTING OR TREATING ATHEROSCLEROSIS, PANCREATITIS SECONDARY TO HYPERTRIGLYCERIDEMIA, HYPERGLYCEMIA, OBESITY BRISTOL-MYERS SQUIBB COMPANY (US) 1998-04-14 — — US disclosed
Send feedback